financetom
Business
financetom
/
Business
/
US regional banks weather CRE storm, office loans continue to lag
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
US regional banks weather CRE storm, office loans continue to lag
Nov 6, 2025 7:15 AM

(Reuters) -U.S. regional banks' commercial real estate loan books are proving broadly resilient despite worries sparked by a handful of soured loans, but the office sector continues to be a pain point, analysts said.

At least eight mid-sized and regional U.S. banks reported lower non-performing loans (NPLs) - loans on which borrowers missed scheduled payments - in their CRE portfolios in the third quarter compared with a year ago, a Reuters analysis of earnings reports showed.

Commercial real estate, mainly office loans, have been under pressure since the COVID-19 pandemic overhauled working habits, and return-to-office mandates have not yet translated into a meaningful rebound in office real estate demand.

Nearly a dozen lenders said they have reduced their concentration of office loans. Flagstar Bank, formerly New York Community Bank, whose CRE troubles sparked a sector-wide crisis of confidence last year, reduced its allowances for credit losses tied to its office portfolio by 142 basis points in the third quarter.

Regions Financial ( RF ), meanwhile, said office loans drove its third-quarter charge-offs, though it expects to resolve those exposures soon.

M&T Bank ( MTB ) also said it plans to continue trimming its office loan portfolio, while Citizens Financial said its office balance declined modestly in the third quarter.

Office property loans are falling behind at record levels, with more than 11.76% now delinquent, data from Trepp showed.

"There is a profound change in the way people work. Office vacancy rates are higher than they were even post the global financial crisis. We definitely haven't worked through all of the office issues," said Thomas Mason, principal analyst at S&P Global.

The challenges are more acute for regional banks which have a higher proportion of CRE loans on their books compared with the global lenders. 

Investor fears over regional banks' CRE exposure were reignited last month when fears of a trouble in the credit markets sparked a selloff across the sector.  

Lenders have been buying time by extending loans and hoping that interest-rate cuts by the Federal Reserve will ease pressure on borrowers, but it is unclear how long that strategy can last with a December cut now in doubt. 

CRE loan pricing tends to follow longer-term Treasury yields rather than short-term policy rates, which means Fed rate cuts take time to filter through.

Even with two cuts since mid-September, new CRE loans issued in 2025 will carry an average interest rate of 6.24%, compared with 4.76% on loans that mature this year, according to S&P Global. 

Roughly $936 billion of U.S. CRE mortgages are set to mature next year, 18.6% higher than in 2025, with maturities expected to peak at $1.1 trillion in 2029, according to S&P Global Market Intelligence estimates. 

"Approximately one-fifth of all maturing commercial real estate loans in 2025 are expected to be office loans," Ermengarde Jabir, director of economic research at Moody's Analytics told Reuters.

"Property types like office have yet to 'recover' and are still posting increasing vacancy rates," she said.

BIOTECH REAL ESTATE PAIN

While office remains the industry's pressure point, landlords and lenders are tightening terms for life sciences real estate as biotech funding slows and fewer companies in the sector are able to tap public markets. 

"A lot of companies, especially small and mid-sized biotechs, have put expansion plans on hold," said Vikram Malhotra, senior equity research analyst at Mizuho Americas.

"These tenants typically operate with four to six quarters of cash runway, but after missing a fundraising round or two, some are running out of money."

The overall lab vacancy rate across the top 13 life sciences markets in the country rose to 22.7% in the second quarter, up 1.2 percentage points from the previous quarter, CBRE data showed.

BANKS STILL DEEP IN CRE

While commercial banks have scaled back CRE lending and sold off portfolios to private credit firms, they still held the largest share of commercial or multifamily mortgages at 38%, totaling $1.8 trillion, according to second quarter data from the Mortgage Bankers Association.

Provisions for loan losses in 2026 could rise to 24% of net revenue, compared with 20.8% this year, wrote Nathan Stovall, director of financial institutions research at S&P Global in a note.

"Banks have arguably benefited from private credit firms growing their market share in CRE. But the industry is not completely out of the woods," he wrote.

(Reporting by Niket Nishant and Manya Saini in Bengaluru; Editing by Michelle Price and Arun Koyyur)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Brazil soybean, cotton traders join other lobbies against tax rule change
Brazil soybean, cotton traders join other lobbies against tax rule change
Jun 6, 2024
SAO PAULO, June 6 (Reuters) - Brazilian soybean and cotton companies on Thursday joined the biofuels and food lobbies to blast new rules for use of tax credits, increasing the odds the measure will be rejected by a Congress heavily influenced by farming interests. Backlash for the measure represents the latest test in President Luiz Inacio Lula da Silva's shaky...
National Bank Maintains Transat Underperform Rating, $2.25 Target After Q2 Result
National Bank Maintains Transat Underperform Rating, $2.25 Target After Q2 Result
Jun 6, 2024
01:47 PM EDT, 06/06/2024 (MT Newswires) -- National Bank is maintaining its Underperform rating and $2.25 target on Transat following its second quarter results. Analyst Cameron Doerksen writes that in mid-May, Transat lowered its F2024 EBITDA margin expectation to ~5% from prior guidance of 7.5%-9% driven by challenges related to engine-related aircraft groundings, the impact from strike threats, and generally...
Exclusive-Chile's Codelco targeting 2030 production for Maricunga lithium site -document
Exclusive-Chile's Codelco targeting 2030 production for Maricunga lithium site -document
Jun 6, 2024
SANTIAGO (Reuters) - Rothschild & Co has formally started to assess candidates to partner with Chile's state-run miner Codelco on a major new lithium project slated to begin production in 2030, according to documents seen by Reuters on Thursday. A four-page investment highlight document from Codelco and Rothschild, dated June 2024, and accompanying memo, reveal new details of Codelco's plans...
Arbutus Biopharma Says Imdusiran Plus VTP-300 Therapy Lowers HBsAg Levels in Trial
Arbutus Biopharma Says Imdusiran Plus VTP-300 Therapy Lowers HBsAg Levels in Trial
Jun 6, 2024
01:49 PM EDT, 06/06/2024 (MT Newswires) -- Arbutus Biopharma ( ABUS ) said Thursday data from a phase 2a trial in patients with chronic hepatitis B virus infection showed that treatment with imdusiran followed by Barinthus Biotherapeutics' ( BRNS ) VTP-300 was generally safe and well-tolerated. Based on preliminary end-of-treatment data, Arbutus said that the therapy resulted in maintenance of...
Copyright 2023-2026 - www.financetom.com All Rights Reserved